Request Legal Help Now - Free

LAWSUITS NEWS & LEGAL INFORMATION

Ketek Approval Still Haunting FDA Part II

. By
Rockville MDThe doctor involved in the Ketek trial has been charged for her actions and sentenced to 57 months in prison after pleading guilty to one count of mail fraud. She enrolled 400 patients into the study, more than any other doctor. At the rate Sanofi-Aventis offered per patient, $400, that was a lot of extra income. Her illegal actions allegedly included forging consent forms and faking data.

A third-party, one that was contracted to oversee Ketek's safety trials, noted irregularities in the doctor's data and had a teleconference with Sanofi-Aventis to inform company officials of the irregularities. However, the drug-maker took no immediate action in the incident.

Ketek healthcare workerMeanwhile the FDA sent its own officials to top-enrolling doctor's offices. In all, the FDA investigators visited ten high-enrolling offices and found serious problems at each office. Despite this, FDA officials told scientists not to inform an advisory panel, one that would recommend whether or not the FDA should approve Ketek, about their concern regarding the validity of Ketek's safety information.

All of this occurred after Ketek was rejected by the FDA. In 2001, Sanofi-Aventis filed for approval but the FDA turned the company down saying that it required additional safety information before it could approve the drug. And yet, despite requesting further safety information and receiving data from a study filled with misinformation, the FDA ultimately approved Ketek for patient use.

Dr. Ross, as quoted in the St. Petersburg Times, noted that Ketek was used for illnesses that often clear up on their own over time. "This was not a drug that anybody thought was necessary in terms of public health," he said. "But it was important for the company financially."

In March 2007 Sanofi-Aventis issued a Dear Healthcare Professional letter advising physicians about new warnings and labels for Ketek. Included in the warnings were "visual disturbances," including "blurred vision, difficulty focusing, and diplopia." Also included in the new warnings was "loss of consciousness," "including some cases associated with vagal syndrome."

Ketek is known generically as telithromycin and was approved by the FDA in 2004. It was initially approved to treat acute bacterial exacerbation of bronchitis and acute bacterial sinusitis. However, it is no longer approved for those conditions and is now only approved to treat community-acquired pneumonia (that is, pneumonia acquired outside of a hospital) of mild to moderate severity. Ketek also now carries a black box warning about potentially deadly side effects including liver failure and aggravation of myasthenia gravis.

READ ABOUT THIS LAWSUIT

Ketek Legal Help

If you or a loved one has suffered severe side effects while taking Ketek, please contact a lawyer involved in a possible [Ketek Lawsuit] who will review your case at no cost or obligation.

ADD YOUR COMMENT ON THIS STORY

Fields marked * are mandatory. Please read our comment guidelines before posting.

*Name:

Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.
*Your Comment:

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.


Click to learn more about LawyersandSettlements.com

Request Legal Help Now! - Free